Business
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
BOSTON, December 08, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Joseph Vittiglio, Esq., as Chief Business and Legal Officer. Mr. Vittiglio brings more than two decades of executive leadership experience across legal, compliance, corporate development, and corporate governance with
About this update from Pepgen Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/e56d8853de34c3b8a89b0bb48fb7a01d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rJPJoHeBeQz8q6x3BgkwYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e56d8853de34c3b8a89b0bb48fb7a01d","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/MDQG6aBhSplOBrK8VZH_bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/e56d8853de34c3b8a89b0bb48fb7a01d","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BOSTON, December 08, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Joseph Vittiglio, Esq., as Chief Business and Legal Officer. Mr. Vittiglio brings more than two decades of executive leadership experience across legal, compliance, corporate development, and corporate governance within public biotechnology companies.","length":551,"tagName":"p"},{"type":"text","content":""Joe is a deeply experienced legal and business leader with a proven track record guiding companies through complex transactions, regulatory milestones, financings, product launches, and strategic partnerships," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "We are excited to welcome him to PepGen’s executive leadership team as we continue to make significant progress advancing our PGN-EDODM1 program and prepare for the anticipated 2026 readouts from the 5 mg/kg and 10 mg/kg cohorts in our FREEDOM2-EDODM1 multiple ascending dose study in DM1 patients."","length":607,"tagName":"p"},{"type":"text","content":"Mr. Vittiglio joins PepGen after providing extensive consulting support to the Company in 2025. He most recently served as Chief Business and Legal Officer and Corporate Secretary at bluebird bio, where he led global legal, compliance, and business development; supported the approval and launch of three U.S. gene therapy products; advanced ex-U.S. partne...